Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ratiopharm gmbh - lamotrigin - dispergerbar tablett - 50 mg - sorbitol hjälpämne; lamotrigin 50 mg aktiv substans - lamotrigin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ratiopharm gmbh - lamotrigin - tablett - 50 mg - laktosmonohydrat hjälpämne; lamotrigin 50 mg aktiv substans - lamotrigin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - lamotrigin - tablett - 50 mg - lamotrigin 50 mg aktiv substans; laktosmonohydrat hjälpämne - lamotrigin

Europeiska unionen - svenska - EMA (European Medicines Agency)

photonamic gmbh & co. kg - 5-aminolevulinsyrahydroklorid - gliom - antineoplastiska medel - gliolan är indicerat hos vuxna patienter för visualisering av malign vävnad under operation för malignt gliom (världshälsoorganisationen iii och iv).

Europeiska unionen - svenska - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiska medel - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienter som har en låg eller mycket låg risk för återfall bör inte få adjuvant behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. förutom vid nyligen diagnostiserad kml kronisk fas, det finns inga kontrollerade studier som visar på en klinisk nytta eller ökad överlevnad för dessa sjukdomar.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hameln pharma gmbh - remifentanilhydroklorid - pulver till koncentrat till injektions-/infusionsvätska, lösning - 1 mg - remifentanilhydroklorid 1,1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hameln pharma gmbh - remifentanilhydroklorid - pulver till koncentrat till injektions-/infusionsvätska, lösning - 2 mg - remifentanilhydroklorid 2,2 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hameln pharma gmbh - remifentanilhydroklorid - pulver till koncentrat till injektions-/infusionsvätska, lösning - 5 mg - remifentanilhydroklorid 5,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ratiopharm gmbh - zolpidemtartrat - filmdragerad tablett - 10 mg - laktosmonohydrat hjälpämne; zolpidemtartrat 10 mg aktiv substans - zolpidem

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ratiopharm gmbh - zolpidemtartrat - filmdragerad tablett - 5 mg - zolpidemtartrat 5 mg aktiv substans; laktosmonohydrat hjälpämne - zolpidem